Home › Companies › IMMX

Pipeline (1 active programs)

Technology platforms

Capital (as filed)

Cash

$225M cash and cash equivalents · Jun 30, 2026 (10-Q)

Short-term investments

$6.6M Jun 30, 2026

Long-term investments

$2.1M Jun 30, 2026

Operating cash flow

−$11.7M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$346M cash, runway mid-2028 per the update of Sep 29, 2026 — the company's own words as read there, not the filed figure

Offering documents (4)

• 2026-09-29 FWP · Pricing term sheet 11.4M shares · at $11.00 · $125M gross · 4.1% below the prior close ($11.47, Sep 28, 2026)
• 2026-09-29 424B5 · Priced offering 11.4M shares · at $11.00 · $125M gross · 4.1% below the prior close ($11.47, Sep 28, 2026)
• 2026-05-21 424B5 · Priced offering 16.8M shares · at $8.94 · $150M gross · 0.0% above the prior close ($8.94, May 20, 2026)
• 2026-05-21 FWP · Pricing term sheet 16.8M shares · at $8.94 · $150M gross · 0.0% above the prior close ($8.94, May 20, 2026)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

• 2026-09-29 UPDATE: Immix Biopharma (IMMX) - The Data Holds, the Clock Slips 🔒 Paid
• 2026-05-21 UPDATE: Immix Biopharma (IMMX) — The 95% CR Lands, and the Dilution Gap Closes Before It Opens 🔒 Paid
• 2026-05-12 Immix Biopharma (IMMX) - Scientific Deep Dive for NXC-201 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Immix Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-05-12 Buy core Immix Biopharma (IMMX) - Scientific Deep Dive for NXC-201 and Pipeline Products Structurally de-risked asset heading into a high-probability Q3 2026 pivotal data readout, with pristine interim CR data, $90.6M cash runway eliminating pre-catalyst dilution risk, and strong M&A optionality.
2. 2026-05-21 Buy core UPDATE: Immix Biopharma (IMMX) — The 95% CR Lands, and the Dilution Gap Closes Before It Opens The 95% CR rate printed exactly as predicted, the post-data dilution risk was pre-emptively defused by a $150M raise extending runway to mid-2028, and M&A optionality is higher with the full data set in hand.
3. 2026-09-29 Buy core UPDATE: Immix Biopharma (IMMX) - The Data Holds, the Clock Slips 89% IRC-adjudicated CR across all 45 patients confirms the science held at scale, balance sheet is fortress-level post-raise, but the catalyst timeline slipped 6-9 months to mid-2027 turning this into a patient hold rather than a near-term trade.

• Long call · opened May 12, 2026 at $10.66 · -24.4% vs XBI +12.8% (Nov 6, 2026)

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 4, 2026ReleaseImmix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
• Oct 5, 2026ReleaseImmix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
• Sep 30, 2026ReleaseImmix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
• Sep 30, 20268-KCurrent report: other events · EX-99.1
• Sep 29, 2026ReleaseImmix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Po→ BD updateSummary on the 8-K
• Sep 29, 2026ReleaseImmix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock→ BD updateSummary on the 8-K
• Sep 29, 2026FWPFree writing prospectus (offering terms)→ BD updateSummary on the 8-K
• Sep 29, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateToday's NEXICART-2 interim data across all 45 patients printed an 89% CR rate — with 4 MRD-negative patients pointing toward 98% — while Immix simultaneously priced a $125M offering at $11.00/share via J.P. Morgan, fortifying the balance sheet but adding another 11.4M shares ahead of the mid-2027 final readout.
• Sep 29, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
• Aug 7, 202610-QQuarterly report
• Aug 4, 2026ReleaseImmix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
• Jul 20, 20268-KCurrent report: other events
• May 29, 20268-KCurrent report: shareholder vote
• May 21, 2026FWPFree writing prospectus (offering terms)
• May 21, 20268-KCurrent report: other events · EX-99.1
• May 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
• May 21, 2026424B5Prospectus supplement (offering)
• May 7, 202610-QQuarterly report
• Apr 6, 2026DEFA14AProxy soliciting material
• Apr 6, 2026DEF 14AProxy statement
• Mar 30, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
• Mar 27, 202610-K/AAnnual report (amended)
• Mar 25, 20268-KCurrent report: material agreement
• Mar 25, 2026424B5Prospectus supplement (offering)
• Mar 25, 202610-KAnnual report